Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant
Por um escritor misterioso
Descrição
New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer: Molecular Therapy - Oncolytics
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Nivolumab Combined With Ipilimumab Shows Activity in Prostate Cancer Subsets - The ASCO Post
ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650
Management of Castration-Resistant Prostate Cancer
Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer - European Urology Focus
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Nivolumab-ipilimumab combination demonstrates antitumor activity in prostate cancer subset
Frontiers Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy
PDF) Long-term complete remission with Ipilimumab in metastatic castrate- resistant prostate cancer: Case report of two patients
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
Cancers, Free Full-Text
Figure 2 from Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
de
por adulto (o preço varia de acordo com o tamanho do grupo)
